GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer

Published on Sep 1, 2017in Gut19.819
· DOI :10.1136/GUTJNL-2015-311256
Paola Martinelli10
Estimated H-index: 10
,
Enrique Carrillo-de Santa Pau17
Estimated H-index: 17
+ 13 AuthorsFrancisco X. Real91
Estimated H-index: 91
(UPF: Pompeu Fabra University)
Sources
Abstract
Background and aims The role of GATA factors in cancer has gained increasing attention recently, but the function of GATA6 in pancreatic ductal adenocarcinoma (PDAC) is controversial. GATA6 is amplified in a subset of tumours and was proposed to be oncogenic, but high GATA6 levels are found in well-differentiated tumours and are associated with better patient outcome. By contrast, a tumour-suppressive function of GATA6 was demonstrated using genetic mouse models. We aimed at clarifying GATA6 function in PDAC. Design We combined GATA6 silencing and overexpression in PDAC cell lines with GATA6 ChIP-Seq and RNA-Seq data, in order to understand the mechanism of GATA6 functions. We then confirmed some of our observations in primary patient samples, some of which were included in the ESPAC-3 randomised clinical trial for adjuvant therapy. Results GATA6 inhibits the epithelial–mesenchymal transition (EMT) in vitro and cell dissemination in vivo. GATA6 has a unique proepithelial and antimesenchymal function, and its transcriptional regulation is direct and implies, indirectly, the regulation of other transcription factors involved in EMT. GATA6 is lost in tumours, in association with altered differentiation and the acquisition of a basal-like molecular phenotype, consistent with an epithelial-to-epithelial (ET 2 ) transition. Patients with basal-like GATA6 low tumours have a shorter survival and have a distinctly poor response to adjuvant 5-fluorouracil (5-FU)/leucovorin. However, modulation of GATA6 expression in cultured cells does not directly regulate response to 5-FU. Conclusions We provide mechanistic insight into GATA6 tumour-suppressive function, its role as a regulator of canonical epithelial differentiation, and propose that loss of GATA6 expression is both prognostic and predictive of response to adjuvant therapy.
Figures & Tables
Download
📖 Papers frequently viewed together
201642.78Nature
1,603 Citations
825 Citations
18 Authors (Eric A. Collisson, ..., Joe W. Gray)
952 Citations
References54
Newest
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours ...
1,603 CitationsSource
#1Paola MartinelliH-Index: 10
#2Francesc MadrilesH-Index: 3
Last. Francisco X. Real (UPF: Pompeu Fabra University)H-Index: 91
view all 7 authors...
Background and aims Gata6 is required to complete and maintain acinar differentiation in the mouse pancreas. Pancreas-specific Gata6 ablation during development causes extensive and persistent acinar-ductal metaplasia, which is considered an initial step of mutant KRas -driven carcinogenesis. Therefore, the Gata6 -null pancreas might represent a tumour-prone environment. We investigated whether Gata6 plays a role during pancreatic tumorigenesis. Design We analysed genetically engineered mouse mo...
56 CitationsSource
#1Seth P. Lerner (BCM: Baylor College of Medicine)H-Index: 75
#2David J. McConkey (University of Texas MD Anderson Cancer Center)H-Index: 108
Last. Francisco X. Real (UPF: Pompeu Fabra University)H-Index: 91
view all 8 authors...
The advent of Omics technologies has been key to the molecular subclassification of urothelial bladder cancer. Several groups have used different strategies to this aim, with partially overlapping findings. The meeting at the Spanish National Cancer Research Center-CNIO was held to discuss such classifications and reach consensus where appropriate. After updated presentations on the work performed by the teams attending the meeting, a consensus was reached regarding the existence of a group of B...
136 CitationsSource
#1Richard A. Moffitt (UNC: University of North Carolina at Chapel Hill)H-Index: 21
#2Raoud Marayati (UNC: University of North Carolina at Chapel Hill)H-Index: 7
Last. Jen Jen Yeh (UNC: University of North Carolina at Chapel Hill)H-Index: 38
view all 18 authors...
Jen Jen Yeh and colleagues apply statistical methods to separate tumor, stroma and normal tissue gene expression signatures from pancreatic ductal adenocarcinoma expression profiling data sets. They identify and validate two tumor-specific and two stroma-specific subtypes, which are associated with different clinical outcomes.
825 CitationsSource
#1Kaja LundH-Index: 8
#2Jennifer L. Dembinski (FHI: Norwegian Institute of Public Health)H-Index: 17
Last. Stefan KraussH-Index: 59
view all 6 authors...
Background Pancreatic adenocarcinoma is a lethal disease with 5-year survival of less than 5%. 5-fluorouracil (5-FU) is a principal first-line therapy, but treatment only extends survival modestly and is seldom curative. Drug resistance and disease recurrence is typical and there is a pressing need to overcome this. To investigate acquired 5-FU resistance in pancreatic adenocarcinoma, we established chemoresistant monoclonal cell lines from the Panc 03.27 cell line by long-term exposure to incre...
29 CitationsSource
Pancreatic cancer remains one of the most lethal of malignancies and a major health burden. We performed whole-genome sequencing and copy number variation (CNV) analysis of 100 pancreatic ductal adenocarcinomas (PDACs). Chromosomal rearrangements leading to gene disruption were prevalent, affecting genes known to be important in pancreatic cancer (TP53, SMAD4, CDKN2A, ARID1A and ROBO2) and new candidate drivers of pancreatic carcinogenesis (KDM6A and PREX2). Patterns of structural variation (var...
1,454 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 67
#2Kimberly D. MillerH-Index: 28
Last. Ahmedin JemalH-Index: 139
view all 3 authors...
Each year the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Regist...
9,503 CitationsSource
#1Patrick C. HermannH-Index: 23
#2Patricia SanchoH-Index: 26
Last. Christopher Heeschen (QMUL: Queen Mary University of London)H-Index: 75
view all 17 authors...
Background & Aims Although smoking is a leading risk factor for pancreatic ductal adenocarcinoma (PDAC), little is known about the mechanisms by which smoking promotes initiation or progression of PDAC. Methods We studied the effects of nicotine administration on pancreatic cancer development in Kras +/LSLG12Vgeo ;Elas-tTA/tetO-Cre (Ela-KRAS) mice, Kras +/LSLG12D ;Trp53+/LSLR172H;Pdx-1-Cre (KPC) mice (which express constitutively active forms of KRAS), and C57/B6 mice. Mice were given nicotine f...
64 CitationsSource
#1Gavin WhissellH-Index: 7
#2Elisa MontagniH-Index: 2
Last. Eduard BatlleH-Index: 45
view all 17 authors...
Batlle and colleagues explore the mechanisms controlling colorectal cancer initiation. They show that GATA6 promotes adenoma stem cell self-renewal and tumour formation by inhibiting BMP signalling.
91 CitationsSource
#1Jeffrey S. Damrauer (UNC: University of North Carolina at Chapel Hill)H-Index: 13
#2Katherine A. Hoadley (UNC: University of North Carolina at Chapel Hill)H-Index: 64
Last. William Y. Kim (UNC: University of North Carolina at Chapel Hill)H-Index: 57
view all 11 authors...
We sought to define whether there are intrinsic molecular subtypes of high-grade bladder cancer. Consensus clustering performed on gene expression data from a meta-dataset of high-grade, muscle-invasive bladder tumors identified two intrinsic, molecular subsets of high-grade bladder cancer, termed “luminal” and “basal-like,” which have characteristics of different stages of urothelial differentiation, reflect the luminal and basal-like molecular subtypes of breast cancer, and have clinically mea...
512 CitationsSource
Cited By114
Newest
#1Rilan Bai (JLU: Jilin University)H-Index: 3
#2Nanya Wang (JLU: Jilin University)H-Index: 5
Last. Jiuwei Cui (JLU: Jilin University)H-Index: 29
view all 5 authors...
Abstract null null Pancreatic ductal adenocarcinoma (PDAC) is a common cause of cancer-related death, and most patients are with advanced disease when diagnosed. At present, despite a variety of treatments have been developed for PDAC, few effective treatment options are available; on the other hand, PDAC shows significant resistance to chemoradiotherapy, targeted therapy, and immunotherapy due to its heterogeneous genetic profile, molecular signaling pathways, and complex tumor immune microenvi...
1 CitationsSource
#1Lijuan Zou (PRC: China Medical University (PRC))
#2Hengpeng He (PRC: China Medical University (PRC))H-Index: 1
Last. Hao Zhang (PRC: China Medical University (PRC))H-Index: 1
view all 0 authors...
Long noncoding RNAs (lncRNAs) are implicated tumor development in a range of different cancers, including pancreatic cancer (PC). Cancer stem cells (CSCs), a drug-resistant cancer cell subset, drive tumor progression in PC. In this work, we aimed to investigate the mechanism by which lncRNA LINC00261 affects the biological functions of CSCs during the progression of PC. Microarray analysis of differentially expressed genes and lncRNAs suggested that LINC00261 is downregulated in PC. Both LINC002...
Source
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease even in the early stages, despite surgical and pharmacological progresses in the latest years. High potential for metastasis is the main cause of therapeutic failure in localized disease, highlighting the current limited knowledge of underneath pathological processes. However, nowadays the research is focusing on the search of personalized approach also in the adjuvant setting for PDAC, by implementing the use of biomarkers and investig...
Source
#1Federica Laudisi (University of Rome Tor Vergata)H-Index: 17
#2Carmine Stolfi (University of Rome Tor Vergata)H-Index: 30
Last. Adelaide Teofani (University of Rome Tor Vergata)
view all 17 authors...
Background & aims null Intestinal barrier dysfunction is a hallmark of inflammatory bowel diseases (IBD), but the mechanisms that lead to such a defect are not fully understood. This study was aimed at characterizing the factors involved in the defective barrier function in IBD. null Methods null Transcriptome analysis was performed on colon samples taken from healthy controls (CTR) and IBD patients. Expression of GATA-binding factor 6 (GATA6), a transcription factor involved in intestinal epith...
Source
#1Yoshinori Endo (Kyoto University)H-Index: 1
#2Ken-ichiro Kamei (SPU: Shenyang Pharmaceutical University)H-Index: 20
Last. Miho Inoue-Murayama (Kyoto University)H-Index: 31
view all 7 authors...
Induced pluripotent stem cells (iPSCs) can provide a biological resource for functional and conservation research in various species. This expectation has led to generation of iPSCs from various species, including those identified as endangered species. However, the understanding of species variation in mammalian iPSCs is largely unknown. Here, to gain insight into the species variation in iPSCs, we the first generated iPSCs from the endangered species Grevy′s zebra (Equus grevyi; gz-iPSCs) for ...
Source
Last. Costello (University of Liverpool)
view all 16 authors...
ObjectiveGATA6 is a master regulator of pancreatic differentiation and a key regulator of the classical phenotype in pancreatic ductal adenocarcinoma (PDAC). Low GATA6 expression is associated with poor patient outcome. GATA4 is the second most expressed GATA factor in the pancreas. The aim was to assess whether, and how, GATA4 contributes to PDAC phenotype and to analyze the association of expression with clinical outcome. null DesignWe analyzed PDAC transcriptomic data, stratifying cases accor...
Source
#1Michael Eyres (University of Oxford)H-Index: 1
#2Simone Lanfredini (University of Oxford)H-Index: 2
Last. Eric O'Neill (University of Oxford)H-Index: 23
view all 24 authors...
Background and Aims Pancreatic ductal adenocarcinoma (PDAC) is characterised by advanced disease stage at presentation, aggressive disease biology and resistance to therapy resulting in extremely poor five-year survival Methods Genome-wide epigenetic mapping of DNA modifications 5-methylcytosine (5mc) and 5-hydroxymethylcytosine (5hmc) using oxidative bisulphite sequencing (oxBS) from formalin embedded sections. Bioinformatics using iCluster and mutational profiling to identify overlap with tran...
1 CitationsSource
#1Julie Dardare (University of Lorraine)H-Index: 1
#2Andréa Witz (University of Lorraine)H-Index: 2
Last. Alexandre Harlé (University of Lorraine)H-Index: 11
view all 7 authors...
Pancreatic ductal adenocarcinoma (PDAC) is one of the malignancies with the worst prognosis despite a decade of efforts. Up to eighty percent of patients are managed at late stages with metastatic disease, in part due to a lack of diagnosis. The effectiveness of PDAC therapies is challenged by the early and widespread metastasis. Epithelial to mesenchymal transition (EMT) is a major driver of cancer progression and metastasis. This process allows cancer cells to gain invasive properties by switc...
Source
#1Kai Duan (UHN: University Health Network)
#2Gun-Ho Jang (OICR: Ontario Institute for Cancer Research)H-Index: 5
Last. Sandra Fischer (UHN: University Health Network)H-Index: 25
view all 9 authors...
Combination chemotherapy, either modified FOLFIRINOX (mFFX) or gemcitabine–nabpaclitaxel, are used in the treatment of most patients with advanced pancreatic ductal adenocarcinoma (PDAC), yet robust biomarkers of outcome are currently lacking to guide regimen selection. Here, we tested GATA6 immunohistochemistry (IHC) as a putative biomarker in advanced PDAC. GATA6 is a transcription factor in normal pancreas development. Two pathologists, blinded to clinical and molecular data, independently as...
1 CitationsSource
#1Koji Miyabayashi (UTokyo: University of Tokyo)H-Index: 24
#2Hayato Nakagawa (UTokyo: University of Tokyo)H-Index: 37
Last. Kazuhiko Koike (UTokyo: University of Tokyo)H-Index: 91
view all 3 authors...
Pancreatic cancer is the most common lethal malignancy, with little improvement in patient outcomes over the decades. The development of early detection methods and effective therapeutic strategies are needed to improve the prognosis of patients with this disease. Recent advances in cancer genomics have revealed the genetic landscape of pancreatic cancer, and clinical trials are currently being conducted to match the treatment to underlying mutations. Liquid biopsy-based diagnosis is a promising...
2 CitationsSource